HIV-1 pNL-BX_pr48V


Product Description

Ref-SKU:
006N-02570
HIV-1, drug resistant point mutant of protease, reported to be selected in vivo during treatment with protease inhibitors, including saaquinavir.
Product Risk Group: 

Information on the related virus

Subspecies: 
Strain: 


Unit definition: 
10 µg purified DNA in TE Buffer

In stock

675,00 €
(Cost per access for Academics)

catalogue

biobank

Portal

EVAg

purchase

buy

order

price

cost

shipping

shipment

experiment

research

laboratory

viral

virus

Cloned Product: Yes
Can it be used to produce GMO: 
No
Biosafety restrictions: 
May reconstitute infectious virus after transfection into suitable human cells
Region encompassed in this Product: 
Full length viral clone
Plasmid: 
Plasmid selection: 
TAG: 
Sequencing: 
Fully sequenced
Sequence checked: 
Yes
Mutations: 
Contain mutations (no frameshift, no unexpected STOP codon)
Observed mutations: 
The virus genome is derived from pNL-NF (pNL4-3 with shortened cellular flank) (doi.org/10.1016/j.jcv.2006.05.001). mutations as indicated in the name; backbone is NL-BX. A unique BamHI site was introduced 5’ of protease (ggagcc2207ggaTcc; A->S in Pol; E->D in Gag) and an XmaI site 3’ of protease (ccagga2589ccCggG). The original BamHI site as position 8465 was removed (GGATCC->GGATCA change silent in Env; L->S in Rev). Other mutations as indicated in the product name.
Storage conditions: 
TE Buffer -20C
Shipping conditions: 
IATA Classification: 
Virus host type: 
Note: 

To identify the resistance(s) to antiretroviral drugs caused by the mutations present in this viral clone, use e.g. the „mutations list analysis“ function of the public HIV-Grade site at:

www.hiv-grade.de/grade_new/

Information about the origin of the product

Recombinant product: 
This product is a recombinant product
Biological material origin: 
Synthetic origin & Natural origin